Generated by AI
Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.
Website2401 Elliott Avenue
Seattle, WA, 98121
United States
The latest articles about CATX.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Feb 2's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Investors talking about CATX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.